Literature DB >> 10694332

The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study.

L D Platt1, R Koch, W B Hanley, H L Levy, R Matalon, B Rouse, F Trefz, F de la Cruz, F Güttler, C Azen, E G Friedman.   

Abstract

OBJECTIVE: The purpose of this report was to update the results of the Maternal Phenylketonuria Collaborative Study, which was established to assess the efficacy of a phenylalanine-restricted diet in preventing morbidity among the offspring of women with hyperphenylalaninemia. STUDY
DESIGN: During a 12-year period 576 women with hyperphenylalaninemia were enrolled in this study. Outcome measures were stratified according to classification of maternal hyperphenylalaninemia and the time at which dietary control of phenylalanine level was achieved.
RESULTS: Optimal physical and cognitive fetal outcomes occurred when maternal blood phenylalanine level <600 micromol/L was achieved by 8 to 10 weeks' gestation and maintained throughout pregnancy (trimester average, </=600 micromol/L).
CONCLUSIONS: The achievement of blood phenylalanine level control through a phenylalanine-restricted diet significantly diminished the occurrence of congenital abnormalities among offspring of women with hyperphenylalaninemia and improved early intellectual progress of these offspring.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694332     DOI: 10.1016/s0002-9378(00)70219-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

Review 1.  Indications for fetal echocardiography.

Authors:  M Small; J A Copel
Journal:  Pediatr Cardiol       Date:  2004 May-Jun       Impact factor: 1.655

Review 2.  Getting to the heart of the matter: epidemiology of cyanotic heart defects.

Authors:  Jennifer L Kornosky; Hamisu M Salihu
Journal:  Pediatr Cardiol       Date:  2008-01-10       Impact factor: 1.655

Review 3.  Emerging issues in public health genomics.

Authors:  Dana Dolinoy; Beth Tarini; J Scott Roberts
Journal:  Annu Rev Genomics Hum Genet       Date:  2014       Impact factor: 8.929

4.  Maternal phenylketonuria: the French survey.

Authors:  François Feillet; Véronique Abadie; Jacques Berthelot; Nicole Maurin; Hélène Ogier; Michel Vidailhet; Jean-Pierre Farriaux; Loic de Parscau
Journal:  Eur J Pediatr       Date:  2004-07-06       Impact factor: 3.183

5.  New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride.

Authors:  Cary O Harding
Journal:  Biologics       Date:  2010-08-09

Review 6.  State-of-the-art 2003 on PKU gene therapy.

Authors:  Zhaobing Ding; Cary O Harding; Beat Thöny
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

Review 7.  Progress toward cell-directed therapy for phenylketonuria.

Authors:  Co Harding
Journal:  Clin Genet       Date:  2008-05-21       Impact factor: 4.438

8.  The Resource Mothers Study of Maternal Phenylketonuria: preliminary findings.

Authors:  F Rohr; A Munier; D Sullivan; I Bailey; M Gennaccaro; H Levy; H Brereton; S Gleason; B Goss; E Lesperance; K Moseley; R Singh; L Tonyes; H Vespa; S Waisbren
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

9.  Cardiac teratogenicity in mouse maternal phenylketonuria: defining phenotype parameters and genetic background influences.

Authors:  Nikki J Seagraves; Kim L McBride
Journal:  Mol Genet Metab       Date:  2012-08-08       Impact factor: 4.797

Review 10.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.